Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380894067> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4380894067 abstract "Abstract Background While cutoffs for abnormal levels of the cerebrospinal fluid (CSF) biomarkers amyloid β 1‐42 (Aβ 1‐42), total tau (t‐tau), phosphorylated tau (p‐tau), and the ratios of t‐tau/Aβ 1‐42 and p‐tau/Aβ 1‐42, have been established in Alzheimer’s disease (AD), biologically relevant cutoffs have not been studied extensively in Parkinson’s disease (PD). We aim to assess the suitability and diagnostic accuracy of established AD‐derived CSF biomarker cutoffs in the PD population. Method Baseline and longitudinal data on CSF biomarkers, cognitive diagnoses, and PET amyloid imaging in 423 newly diagnosed patients with PD from the Parkinson’s Progression Markers Initiative (PPMI) cohort were used to evaluate established AD biomarker cutoffs compared with optimal cutoffs derived from the PPMI cohort. Result Using PET amyloid imaging as the gold standard for AD pathology, the optimal cutoff of Aβ 1‐42 was higher than the AD cutoff, the optimal cutoffs of t‐tau/Aβ 1‐42 and p‐tau/Aβ 1‐42 were lower than the AD cutoffs, and their confidence intervals (CIs) did not overlap with the AD cutoffs. Optimal cutoffs for t‐tau and p‐tau to predict cognitive impairment were significantly lower than the AD cutoffs, and their CIs did not overlap with the AD cutoffs. Conclusion Optimal cutoffs for the PPMI cohort for Aβ 1‐42, t‐tau/Aβ 1‐42, and p‐tau/Aβ 1‐42 to predict amyloid‐PET positivity and for t‐tau and p‐tau to predict cognitive impairment differ significantly from cutoffs derived from AD populations. The presence of additional pathologies such as alpha‐synuclein in PD may lead to disease‐specific CSF biomarker characteristics." @default.
- W4380894067 created "2023-06-17" @default.
- W4380894067 creator A5023136222 @default.
- W4380894067 creator A5035423719 @default.
- W4380894067 creator A5037362183 @default.
- W4380894067 creator A5046674053 @default.
- W4380894067 creator A5058333204 @default.
- W4380894067 creator A5073135371 @default.
- W4380894067 creator A5081337965 @default.
- W4380894067 date "2023-06-01" @default.
- W4380894067 modified "2023-09-27" @default.
- W4380894067 title "Appropriateness of applying CSF biomarker cutoffs from Alzheimer’s disease to Parkinson’s disease" @default.
- W4380894067 doi "https://doi.org/10.1002/alz.065161" @default.
- W4380894067 hasPublicationYear "2023" @default.
- W4380894067 type Work @default.
- W4380894067 citedByCount "0" @default.
- W4380894067 crossrefType "journal-article" @default.
- W4380894067 hasAuthorship W4380894067A5023136222 @default.
- W4380894067 hasAuthorship W4380894067A5035423719 @default.
- W4380894067 hasAuthorship W4380894067A5037362183 @default.
- W4380894067 hasAuthorship W4380894067A5046674053 @default.
- W4380894067 hasAuthorship W4380894067A5058333204 @default.
- W4380894067 hasAuthorship W4380894067A5073135371 @default.
- W4380894067 hasAuthorship W4380894067A5081337965 @default.
- W4380894067 hasBestOaLocation W43808940671 @default.
- W4380894067 hasConcept C121332964 @default.
- W4380894067 hasConcept C126322002 @default.
- W4380894067 hasConcept C142724271 @default.
- W4380894067 hasConcept C143998085 @default.
- W4380894067 hasConcept C2778217198 @default.
- W4380894067 hasConcept C2779134260 @default.
- W4380894067 hasConcept C2779483572 @default.
- W4380894067 hasConcept C2779651940 @default.
- W4380894067 hasConcept C2781197716 @default.
- W4380894067 hasConcept C2908647359 @default.
- W4380894067 hasConcept C55493867 @default.
- W4380894067 hasConcept C62520636 @default.
- W4380894067 hasConcept C71924100 @default.
- W4380894067 hasConcept C72563966 @default.
- W4380894067 hasConcept C86803240 @default.
- W4380894067 hasConcept C99454951 @default.
- W4380894067 hasConceptScore W4380894067C121332964 @default.
- W4380894067 hasConceptScore W4380894067C126322002 @default.
- W4380894067 hasConceptScore W4380894067C142724271 @default.
- W4380894067 hasConceptScore W4380894067C143998085 @default.
- W4380894067 hasConceptScore W4380894067C2778217198 @default.
- W4380894067 hasConceptScore W4380894067C2779134260 @default.
- W4380894067 hasConceptScore W4380894067C2779483572 @default.
- W4380894067 hasConceptScore W4380894067C2779651940 @default.
- W4380894067 hasConceptScore W4380894067C2781197716 @default.
- W4380894067 hasConceptScore W4380894067C2908647359 @default.
- W4380894067 hasConceptScore W4380894067C55493867 @default.
- W4380894067 hasConceptScore W4380894067C62520636 @default.
- W4380894067 hasConceptScore W4380894067C71924100 @default.
- W4380894067 hasConceptScore W4380894067C72563966 @default.
- W4380894067 hasConceptScore W4380894067C86803240 @default.
- W4380894067 hasConceptScore W4380894067C99454951 @default.
- W4380894067 hasIssue "S2" @default.
- W4380894067 hasLocation W43808940671 @default.
- W4380894067 hasOpenAccess W4380894067 @default.
- W4380894067 hasPrimaryLocation W43808940671 @default.
- W4380894067 hasRelatedWork W1985396199 @default.
- W4380894067 hasRelatedWork W1986398611 @default.
- W4380894067 hasRelatedWork W2037414479 @default.
- W4380894067 hasRelatedWork W2105060351 @default.
- W4380894067 hasRelatedWork W2315085516 @default.
- W4380894067 hasRelatedWork W2603773853 @default.
- W4380894067 hasRelatedWork W2804922289 @default.
- W4380894067 hasRelatedWork W3178774655 @default.
- W4380894067 hasRelatedWork W4221019746 @default.
- W4380894067 hasRelatedWork W3184937105 @default.
- W4380894067 hasVolume "19" @default.
- W4380894067 isParatext "false" @default.
- W4380894067 isRetracted "false" @default.
- W4380894067 workType "article" @default.